Related Experiment Videos
Protection against cisplatin nephrotoxicity by prochlorperazine
1Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02115.
Cancer Chemotherapy and Pharmacology
|January 1, 1989
Summary
Prochlorperazine (PCPZ) effectively protects against cisplatin (CDDP)-induced kidney damage in mice and rats. This antiemetic drug may offer therapeutic benefits when combined with CDDP chemotherapy.
Area of Science:
- Nephrology
- Pharmacology
- Oncology
Background:
- Cisplatin (CDDP) chemotherapy is limited by significant renal toxicity.
- Prochlorperazine (PCPZ) has demonstrated protective effects against various nephrotoxicants in preclinical models.
Purpose of the Study:
- To investigate the potential of PCPZ to mitigate CDDP-induced nephrotoxicity.
- To evaluate PCPZ's impact on CDDP's antitumor efficacy and platinum pharmacokinetics.
Main Methods:
- Rats and mice were treated with CDDP, with or without PCPZ.
- Renal injury was assessed by measuring blood urea nitrogen (BUN), glucosuria, and enzymuria.
- Platinum levels in plasma and renal tissue, as well as CDDP's antitumor activity, were evaluated.
Main Results:
- PCPZ significantly ameliorated CDDP-induced increases in BUN, glucosuria, and enzymuria in both species.
- Complete protection against elevated BUN was observed in mice at a PCPZ dose of 10 mg/kg.
- PCPZ reduced total plasma platinum but did not alter platinum excretion, renal platinum levels, or CDDP's in vivo antitumor activity.
Conclusions:
- PCPZ demonstrates significant nephroprotective effects against CDDP-induced renal injury.
- PCPZ may be a valuable adjunct therapy with CDDP, offering renal protection without compromising antitumor efficacy.